Skip to content

Leadership

Management Team

Rick Wypych

Rick Wypych

President & Chief Executive Officer

Rick Wypych joined Cardiac Dimensions in 2003 and has served in a number of roles within the company. Rick has nearly 30 years of operational, financial, and strategic management experience in the financial, manufacturing and life sciences industries.

Prior to joining Cardiac Dimensions, Rick served as Director of Finance and Administration at Spinal Dynamics Corporation, an early-stage artificial intervertebral disc company. He was responsible for finance and accounting, human resources, and administration. During his tenure at Spinal Dynamics, Rick was instrumental in developing the initial revenues of the company, the financing of operations and the eventual sale of the company to Medtronic, Inc. Before joining Spinal Dynamics, he served as a Senior Audit Manager for KPMG LLP managing several financial audit engagements, mergers and acquisitions projects and SEC registrations.

Rick was also a member of the Board of Directors of Simplify Medical prior to its sale to NuVasive, Inc.

Rick holds a Bachelor of Arts degree in Business Administration from Albers School of Business at Seattle University and is a licensed Certified Public Accountant in the State of Washington.

Bob Calcote

Bob Calcote

Vice President, Operations & Compliance

Bob Calcote joined Cardiac Dimensions as Vice President of Operations in March 2014, bringing with him 40 years of manufacturing and engineering experience with more than 30 years in medical device operations, product development, regulatory, and quality system management.

Since 2000, Bob has held a number of senior management positions, serving as Vice President of Operations at RS Medical, Senior Vice President of Operations at ConforMIS, Vice President of Operations at Archus Orthopedics, and Vice President of Operations at Spinal Dynamics, where his management responsibilities included the manufacturing, product development, quality and regulatory activities. Earlier in his career, Bob was the Director of Manufacturing at C.R. Bard’s Impra Division, managing the ePTFE and polyester vascular graft manufacturing operations in the U.S. and France.

Bob received a Bachelor of Science degree in Electrical Engineering and a Master of Science degree in Biomedical Engineering from the University of Texas, Arlington.

Carmelo Mastrandrea

Carmelo Mastrandrea

Vice President, Sales

Carmelo Mastrandrea joined Cardiac Dimensions in 2019, bringing with him almost 20 years of experience in sales, 14 of which are in the medical device industry, including more than 10 years in cardiovascular medical devices.

Prior to joining Cardiac Dimensions, Carmelo was at REVA Medical as Vice President of Sales, Europe. Carmelo also served as General Manager for Biosensors Europe SA’s business in the D-A-CH region (Germany, Austria, and Switzerland) and held management positions with Biotronik Schweiz AG and Guidant AG.

Carmelo received Swiss Federal diplomas in Machine Engineering from Mitecha Engineering School in Aarau and Business from KV Business School in Basel.

Angie Swenson

Angie Swenson

Vice President, Clinical

Angie Swenson joined Cardiac Dimensions in 2023 and has over 15 years of experience in the medical device industry as a leader in the strategic planning and execution of clinical trials and approvals. 

Her leadership led to successful execution of global clinical trials in the United States, Canada, Europe, and Japan for prosthetic heart valves to support regulatory approvals.  She has also strategically managed global studies for drug coated balloons for peripheral vascular disease, renal denervation trials, and hypothermia treatment for acute MI. 

Angie holds a Bachelor’s of Science degree in Medical Technology and a certification from the University of Chicago Graham School for Clinical Trial Management.

Steven Goldberg, MD, FSCAI

Steven Goldberg, MD, FSCAI

Chief Clinical Officer

Steven Goldberg, MD, joined Cardiac Dimensions in 2006. In addition to serving as Chief Clinical Officer for Cardiac Dimensions, Dr. Goldberg is a practicing interventional cardiologist and the medical director for structural heart disease at Community Hospital of the Monterey Peninsula in Monterey, Ca.

Previously Dr. Goldberg served as an Associate Professor of Medicine and Director of the Cardiac Catheterization Lab at University of Washington Medical Center.

Dr. Goldberg received a medical degree and bachelors of arts from the University of Kansas and completed Fellowships in Internal Medicine and Cardiology at Cedars-Sinai Medical Center and the University of California, Irvine respectively.

Satya Shreenivas, MD

Satya Shreenivas, MD

Chief Medical Officer

Satya Shreenivas, MD, joined Cardiac Dimensions in 2024. In addition to serving as Chief Medical Officer for Cardiac Dimensions, Dr. Shreenivas is a practicing interventional cardiologist and brings his rich experience in both the clinical and commercial aspects of the structural heart landscape to his new role with Cardiac Dimensions.

Previously Dr. Shreenivas led the structural heart program and cardiac catheterization laboratory at the University of Cincinnati and spent several years with The Christ Hospital in Ohio where he served as an investigator in many high-profile clinical trials, including several significant structural heart studies.

Dr. Shreenivas trained at the University of Pennsylvania and has an MBA from the Wharton School.

Board Members

Rick Wypych

President & Chief Executive Officer

Rick Wypych joined Cardiac Dimensions in 2003 and has served in a number of roles within the company. Rick has nearly 30 years of operational, financial, and strategic management experience in the financial, manufacturing and life sciences industries.

Prior to joining Cardiac Dimensions, Rick served as Director of Finance and Administration at Spinal Dynamics Corporation, an early-stage artificial intervertebral disc company. He was responsible for finance and accounting, human resources, and administration. During his tenure at Spinal Dynamics, Rick was instrumental in developing the initial revenues of the company, the financing of operations and the eventual sale of the company to Medtronic, Inc. Before joining Spinal Dynamics, he served as a Senior Audit Manager for KPMG LLP managing several financial audit engagements, mergers and acquisitions projects and SEC registrations.

Rick was also a member of the Board of Directors of Simplify Medical prior to its sale to NuVasive, Inc.

Rick holds a Bachelor of Arts degree in Business Administration from Albers School of Business at Seattle University and is a licensed Certified Public Accountant in the State of Washington.

Fouad Azzam

Life Science Partners

Fouad Azzam, PhD, MBA, joined Life Science Partners (LSP) in 2007. He became a General Partner of the firm in that same year. Fouad’s prime focus and responsibility within LSP is to invest in unlisted securities and manage the firm’s North American operations.

Prior to joining LSP, Fouad was the Managing Director of Eastman Ventures, the investment arm of Eastman Chemical Company, where he built-up its Healthcare and Advanced Materials practice. In his role as Managing Director, he was responsible for numerous early- and late-stage investments across the US & Europe. Fouad brings a wealth of investment expertise to the LSP team. Prior to his role at Eastman Ventures, Fouad held senior leadership positions at Eastman Chemical including roles in Innovation, Corporate Strategy, Corporate Development (M&A) and New Business Development. His career also includes business, operating, and technology roles at Occidental Chemical and BFGoodrich.

Among others, Fouad is currently a Director at Illuminoss Medical, a company championing minimally invasive solutions for the stabilization and treatment of bone fractures. Fouad’s academic credentials include a master’s degree and PhD in Chemical Engineering from the University of Akron in Ohio. In addition, Fouad obtained a master of business administration degree in Finance and Strategy from the University at Buffalo in New York.

Mark Carnegie

M. H. Carnegie & Co.

Mark Carnegie is the Founder and Managing Director of M. H. Carnegie & Co. Mark has more than 30 years of experience as an entrepreneur, investor and corporate adviser in New York, London and Sydney.

He co-founded leading Australian boutique corporate advisory, venture capital and private equity firm Carnegie, Wylie & Co with John Wylie in 2000. In August 2007, Carnegie Wylie was acquired by leading Wall Street bank, Lazard Inc.

Prior to Carnegie Wylie, Mark trained on Wall Street with James D. Wolfensohn and worked with Lloyd Williams at Hudson Conway in London. Mark was the Australian and Asian representative of Hellman & Friedman for much of the 1990s. In addition to being involved in a range of diverse Australian and Asian investments, Mark has been a participant in groups that have acquired major stakes in the Courage Pub Estate, John Fairfax Holdings, Hoyts Cinemas, Formula One Holdings, SCTV, Macquarie Radio Network and Lonely Planet Publications and London Sumatra Plantations. As a corporate adviser, Mark has advised Qantas and Coles Myer on general strategic matters, Westfield on its $22 billion merger and Qantas on its JetStar Asia start-up in Singapore.

Mark holds a bachelor of arts degree from Oxford University and a BSc (Hons) from Melbourne University. He is a former Treasurer of the Oxford Union.

Daniel Hetu

Lumira Ventures

With 20 years of investment banking, corporate and business development, and licensing experience, Daniel has been involved with life science companies at all stages of development in North America and overseas.

Before joining Lumira Ventures in 2005, Daniel located in Montréal, spent 10 years at Shire Pharmaceuticals and at Biochem Pharma prior to its acquisition by Shire as Vice President, Business Development North America (Shire), and Vice President, Corporate Development (Biochem Pharma). During that period, he was involved with the in-licensing of a wide range of products and technologies as well as several financing and M&A transactions in the therapeutics, vaccine and diagnostics sectors. At Biochem, Daniel served on the Company’s portfolio committee and the steering committee of strategic research collaborations.

Prior to joining Biochem Pharma, Daniel was an investment banker at a major Canadian investment bank where he was involved in M&A and financing transactions across various industrial sectors.

Daniel holds an MD from Université de Sherbrooke, Québec, and an MBA from École des Hautes Études Commerciales (Montréal, Québec).

Paul McCreadie

Arboretum Ventures

Paul McCreadie oversees Arboretum Ventures’s investment process and leads the firm’s operations. His portfolio investments focus on capital-efficient health IT and service companies applying technology to underserved markets.

Paul currently serves as a Board Director for BioIQ, VYDENCE Medical, and Delphinus Medical and is the former Chief Operating Officer for CerviLenz (now Lucina), where he led the design of the company’s first commercial product from concept to launch.

Prior to joining Arboretum, Paul worked at Ford Motor Company holding management positions within product development, manufacturing, and business strategy. He currently serves on the National Advisory Board for the Institute for Healthcare Policy & Innovation at the University of Michigan.

Paul earned a bachelor of science degree and master of science degree in Mechanical Engineering from the University of Michigan and a master of business administration from the Ross School of Business at the University of Michigan.

Matt McNamara

Horizon 3 Healthcare

Mr. McNamara joined the Board in December 2022. He has over 30 years’ experience in the healthcare and medical sciences sector.

In 2003, he founded BioBridge Australia, a biotechnology commercialisation advisory company and advised a number of public biotechnology / investment companies. He is presently a director of Adherium Ltd (ASX:ADR), SciCapital Pty Ltd and Grey Innovation Group Pty Ltd. He has held previous directorship in, Avita Medical Ltd, Bioxyne Ltd, and Rex Bionics Pty Ltd.

Mr. McNamara has also served as CIO of BioScience Manager Pty Ltd, was CEO of SciCapital Pty Ltd, a Life Sciences Venture Capital fund, SVP Business Development for eBioinformatics Inc, General Manager of Vistakon Pty Ltd (a Johnson & Johnson Medical franchise), and held numerous management positions in Australia with Merck & Co.

Mr. McNamara has a BSc (Hons) in Molecular Biology and is also a holder of an MBA.

Trevor Moody

TM Strategic Advisors LLC

Trevor Moody is currently a Managing Director at M.H. Carnegie & Co. Trevor brings significant experience with more than 25 years in the development, commercialization and funding of innovative, growth-oriented medical technologies.

He was most recently a General Partner at Frazier Healthcare Ventures, a leading healthcare venture capital and private equity investment firm with more than $2.0 billion under management. Trevor co-led the medical device team for almost a decade at Frazier and became known as an active and well-regarded investor. Prior to Frazier Healthcare, he was a Senior Consultant at The Wilkerson Group.

Trevor graduated from Massachusetts Institute of Technology with a masters of science degree in Management (Sloan School) and the University of Southern Queensland, Australia, with a Bachelor of Electrical Engineering. Trained as a Biomedical Engineer, he held product development and marketing roles at Telectronics Pacing Systems and Ventritex, both in the cardiology market.

Trevor is immediate past Board Chair of the Center for Infectious Disease Research, one of the largest independent, non-profit research institutes focused on diseases of the developing world. He is also a board member of electroCore, Serene Medical, and Simplify Medical.

Bob White

Independent Board Member

Bob White has nearly 30 years of experience leading early-stage companies and Fortune 500 business units within the medical technology sector. Bob most recently served as President and Chief Executive Officer of Entellus Medical, Inc., which was acquired by Stryker in February 2018.

Bob made a measurable impact at Entellus as a strong and passionate leader within the ear, nose and throat surgery space, driving his business to successfully treat more than 250,000 patients suffering from chronic sinusitis, Eustachian tube dysfunction and airway obstruction. In 2018, Bob was recognized as a finalist in the Ernst & Young Entrepreneur of the Year and the YPO Global Innovation Award. Bob currently serves as a Director on the Board of portfolio companies Cardiva Medical (acquired by Haemonetics) and TissueTech.

Previously, Bob was the President and Chief Executive Officer of TYRX, Inc., which specialized in commercializing innovative, implantable combination drug and device products focused on infection control until TYRX was sold to Medtronic in 2014. Along the way, TYRX was named to the Fierce Medical Devices “Fierce 15,” designating it as one of the leading medical device and diagnostic companies.

Prior to joining TYRX, Bob held several executive positions with Medtronic, including serving as President of Physio Control, Vice President of Commercial Operations of the Cardiac Rhythm Disease Management business, and President of Kyphon following its $3.9 billion acquisition of the spinal treatment business. Earlier in his career, Bob held leadership positions in business development, international sales and marketing, operations, and general management with Instromedix/Life Watch, Eli Lilly, IVAC/Alaris Medical, and General Electric.

Bob currently also serves as a Director on the Board of Atricure Inc. (NASDAQ: ATRC). During the past year, two other companies that Bob actively served as a Director for were acquired for significant premiums, including Novadaq Technologies and privately held Hyperbranch Medical Technology.

Bob holds a bachelors of science degree in Aerospace Engineering from the University of Missouri-Rolla and a master of business administration degree from Cornell University.

Join our mailing list for invitations to studies along with company announcements.

    Cardiac Dimensions logo - horizontal

    © 2023 Cardiac Dimensions. All rights reserved.

    *NOTE: The Carillon Mitral Contour System has received CE Mark (0344) and is available for sale in Europe and other countries that recognize CE Mark.

    CAUTION: Investigational Device. Limited by United States law to investigational use.

    Cardiac Dimensions logo - horizontal

    © 2022 Cardiac Dimensions. All rights reserved.

    *NOTE: The Carillon Mitral Contour System has received CE Mark (0344) and is available for sale in Europe and other countries that recognize CE Mark.

    CAUTION: Investigational Device. Limited by United States law to investigational use.